Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5701 Target Snapshot

Serine/threonine-protein kinase TAO3 · SINGLE PROTEIN · Homo sapiens

806Compounds
204Assays
14Approved Drugs
451.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9H2K8. Use UniProt Q9H2K8 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9H2K8 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase TAO3 as ChEMBL target CHEMBL5701, mapped to UniProt Q9H2K8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase TAO3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5701
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9H2K8
Serine/threonine-protein kinase TAO3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase TAO3 is the right protein anchor across sources, using UniProt Q9H2K8 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase TAO3
UniProt AccessionQ9H2K8
Component TypeProtein
Sequence Length898 aa

Serine/threonine-protein kinase TAO3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase TAO3, mapped to UniProt Q9H2K8. Sequence length is 898 aa.

Mapped IDQ9H2K8
Review nameSerine/threonine-protein kinase TAO3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

14
Approved
8
Phase III
13
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC50121.0
KD330.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.66 Kd 0.22 Preclinical
CHEMBL388978 8.96 IC50 1.09 Preclinical
CHEMBL574738 8.24 Kd 5.8 Preclinical
CHEMBL3688339 7.68 Kd 21.0 Preclinical
CHEMBL450786 7.37 Kd 43.0 Preclinical
CHEMBL509032 7.36 Kd 44.0 Preclinical
CHEMBL2334586 7.35 IC50 45.0 Preclinical
CHEMBL477772 7.35 Kd 45.0 Approved
CHEMBL3717287 7.3 IC50 50.0 Preclinical
CHEMBL3717391 7.3 IC50 50.0 Preclinical
Distribution

pChEMBL Value Distribution

10
5.0
20
5.5
24
6.0
9
6.5
49
7.0
1
7.5
1
8.0
3
8.5
0
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

BOSUTINIB
CHEMBL288441
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
RUXOLITINIB
CHEMBL1789941
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

204
Total Assays
116
Tested Compounds
1
Assay Types
Binding — 204 assays, 116 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 156 45 6.5
assay format 20 51 7.1
cell-based format 18 0
subcellular format 10 20 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine